TURKU, FI / ACCESS Newswire / May 30, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Phase I study shows promising clinical activity and tolerability of bexmarilimab plus standard-of-care in ...

Acute myeloid leukemia (AML) is increasingly being recognized as a national health priority due to rising cases. Despite ...

Don't dismiss persistent fatigue and bruising. These 11 warning signs could indicate acute myelogenous leukemia hiding in ...

Learn about acute myelogenous leukemia (AML), its sneaky symptoms, aggressive nature, and how bone marrow produces defective ...

Medically reviewed by Archana Sharma, DO Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a type of ...

Ziftomenib also showed a favorable safety profile, with limited myelosuppression and only 3% of patients discontinuing due to ...

An international study has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn't work for everyone. The findings could help doctors better match patients with the therapies ...

Overall survival analysis showed median survival duration of 53.9 months (95% CI, 23.4 to not estimable) in the nivolumab arm ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute ...

An international study led by the University of Colorado Cancer Center has uncovered why a widely used treatment for acute myeloid leukemia (AML) doesn’t work for everyone. The findings could help ...